Cancer Lett. 2025 Jan 12;612:217462. doi: 10.1016/j.canlet.2025.217462. Online ahead of print.

ABSTRACT

A user-friendly integrated database, RMethyMD (http://www.tmliang.cn/rnamethy), was developed to provide a comprehensive analysis of methylation regulators aimed at facilitating the exploration of molecular features in tumorigenesis and clinical implications in cancer diagnosis and treatment via a multiomics approach. Subsequently, molecular landscapes and a robust constructed m6A-based prognostic model using coxBoost + RSF algorithms in lung cancer highlighted m6A as a suitable marker to guide therapeutic strategy. RMethyMD provides a comprehensive resource and multiomics analysis to explore m6A-based prognostic and clinical values, thereby contributing to aiding personalized cancer therapy.

PMID:39809358 | DOI:10.1016/j.canlet.2025.217462